

SUPPLEMENTAL TABLE 2 (continued)

FDA-APPROVED THERAPEUTICS FOR THE TREATMENT OF CANCER

DNA Repair Inhibitors

| Approved Indication | Generic Name | Trade Name |
|--|--------------|------------|
| certain types of ovarian, fallopian tube, and primary peritoneal cancers | niraparib | Zejula |
| certain forms of breast and ovarian cancers | olaparib* | Lynparza |
| certain type of ovarian cancer | rucaparib* | Rubraca |
| certain type of breast cancer | talazoparib* | Talzenna |

Immune Checkpoint Inhibitors

| Approved Indication | Generic Name | Trade Name |
|--|-----------------|------------|
| certain types of bladder, breast, and lung cancers | atezolizumab | Tecentriq |
| certain types of bladder, kidney, and skin cancers | avelumab | Bavencio |
| certain type of skin cancer | cemiplimab-rwlc | Libtayo |
| certain types of bladder cancer and lung cancer | durvalumab | Imfinzi |
| multiple cancers | ipilimumab | Yervoy |
| multiple cancers | nivolumab | Opdivo |
| multiple cancers | pembrolizumab | Keytruda |

Bone-remodeling Inhibitors

| Approved Indication | Generic Name | Trade Name |
|--|--------------|------------|
| potentially lethal complication of advanced cancers* | denosumab | Xgeva |

Angiogenesis Inhibitors

| Approved Indication | Generic Name | Trade Name |
|--|--------------|---------------------|
| kidney cancer | axitinib | Inlyta |
| multiple cancers | bevacizumab | Avastin |
| thyroid cancer; kidney cancer; liver cancer | cabozantinib | Cometriq; Cabometyx |
| certain type of thyroid cancer; kidney cancer; liver cancer | lenvatinib | Lenvima |
| kidney cancer; soft tissue sarcomas; gastrointestinal stromal tumors | pazopanib | Votrient |
| certain types of lung, stomach, and liver cancers | ramucirumab | Cyramza |

| | | |
|---|-----------------|----------|
| colorectal cancer; gastrointestinal stromal tumors and liver cancer | regorafenib | Stivarga |
| kidney cancer; certain type of thyroid cancer | sorafenib | Nexavar |
| gastrointestinal stromal tumors; kidney cancer; some pancreatic cancers | sunitinib | Sutent |
| thyroid cancer | vandetanib | Caprelsa |
| colorectal cancer | ziv-aflibercept | Zaltrap |

Cell Lysis Mediators

| Approved Indication | Generic Name | Trade Name |
|--|----------------------------|------------|
| certain leukemias | alemtuzumab | Campath |
| certain types of leukemia | blinatumomab | Blinicyto |
| certain lymphomas | brentuximab vedotin | Adcetris |
| multiple myeloma | daratumumab | Darzalex |
| neuroblastoma | dinutuximab | Unituxin |
| multiple myeloma | elotuzumab | Empliciti |
| certain lymphomas | ibritumomab | Zevalin |
| certain types of non-Hodgkin lymphoma | mogamulizumab-kpkc | Poteligeo |
| certain type of leukemia | moxetumomab pasudotox-tdfk | Lumoxiti |
| certain form of leukemia; certain form of lymphoma | obinutuzumab | Gazyva |
| certain leukemias | ofatumumab | Arzerra |
| certain lymphomas | rituximab | Rituxan |
| certain type of leukemia | tagraxofusp-erzs | Elzonris |

INCREASING PRECISION

Oncolytic Virus

| Approved Indication | Generic Name | Trade Name |
|---------------------|--------------------------|------------|
| melanoma | talimogene laherparepvec | Imlygic |

Therapeutic Vaccines

| Approved Indication | Generic Name | Trade Name |
|---------------------|--------------|------------|
| prostate cancer | sipuleucel-T | Provenge |

CAR T-cell Therapy

| Approved Indication | Generic Name | Trade Name |
|--|-------------------------|------------|
| certain type of non-Hodgkin lymphoma | axicabtagene ciloleucel | Yescarta |
| certain types of leukemia and non-Hodgkin lymphoma | tisagenlecleucel | Kymriah |

* includes companion diagnostic

Some drugs are available in multiple formulations; these have only been listed once. Where multiple trade names are used, only the most common have been listed.